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Abstract
Oral Squamous Cell Carcinoma (OSCC) has a very flagitious treatment regime. A prodrug approach is thought to aid in
targeting chemotherapy. CYP1B1, a member of cytochrome P450 family, has been implicated in chemical carcinogenesis.
There exists a general accordance that this protein is overexpressed in a variety of cancers, making it an ideal candidate for a
prodrug therapy. The activation of the prodrug facilitated by CYP1B1 would enable the targeting of chemotherapy to tumor
tissues in which CYP1B1 is specifically overexpressed as a result reducing the non-specific side effects that the current
chemotherapy elicits. This study was aimed at validating the use of CYP1B1 as a target for the prodrug therapy in OSCC. The
expression profile of CYP1B1 was analysed in a panel of 51 OSCC tumors, their corresponding normal tissues, an epithelial
dysplasia lesion and its matched normal tissue by qRT-PCR, Western blotting and Immunohistochemistry. CYP1B1 was found
to be downregulated in 77.78% (28/36) tumor tissues in comparison to their corresponding normal tissues as well as in the
epithelial dysplasia lesion compared to its matched normal tissue at the transcriptional level, and in 92.86% (26/28) of tumor
tissues at the protein level. This report therefore clearly demonstrates the downregulation of CYP1B1 at the transcriptional
and translational levels in tumor tissues in comparison to their corresponding normal tissues. These observations indicate
that caution should be observed as this therapy may not be applicable universally to all cancers and also suggest the
possibility of a prophylactic therapy for oral cancer.
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Introduction
Oral squamous cell carcinoma (OSCC) is the most common
head and neck cancer, with a worldwide incidence of 640,000 new
cases annually [1]. Disappointingly, survival rates of OSCC have
not improved since the last many decades. Both smoked and
smokeless forms of tobacco are major inducers of OSCC [2].
Cigarette smoke has been shown to upregulate cytochrome P450
(CYP1B1 and CYP1A1) under in vitro conditions as well as in
smokers [3–5]. The CYP1B1 gene is transcriptionally activated by
polycyclic aromatic hydrocarbons which are major constituents of
cigarette smoke and tobacco, making it responsive to smoked and
smokeless (chewing) tobacco [6–8]. CYP1B1 plays a role in the
bioactivation of chemically diverse tobacco related procarcinogens
to reactive metabolites. Thus, the expression of CYP1B1 is
considered to be an important determinant of carcinogenesis [9].
It has been observed that CYP1B1 is overexpressed in a wide array
of human tumors compared to their respective normal tissues
[8,10,11]. Allelic variations in CYP1B1 have also been shown to
modulate the incidence of several types of cancers [12,13].
CYP1B1 has also been implicated in aiding resistance to
tamoxifen, docetaxel and flutamide [11]. Thus, CYP1B1 appears
to play an important role incarcinogenesis as well as therapeutics.
Differential expression of CYP1B1 in tumor cells creates an
opportunity to develop potential strategies that may involve either
inhibiting CYP1B1 activity (which as stated above activates
procarcinogens) or using the metabolic activity of CYP1B1 to
activate essentially non-toxic prodrugs (e.g., resveratrol and aryl
oxime) to cytotoxic compounds. Therapies based on these prodrugs
are in preclinical evaluations [14] and clinical trials for colorectal
cancer, melanoma and follicular lymphoma (http://clinicaltrials.
gov/ct2/results?term=resveratrol). The overall aim of this study
was to validate CYP1B1 as a therapeutic target in OSCC. Although
previous studies have suggested CYP1B1 protein expression to be
tumor specific [9,15], our observations clearly indicate that the
protein is not only expressed in normal as well as tumor tissues, but
is also downregulated in oral tumor tissues.
Results
Determination of CYP1B1 mRNA levels
All the 36 matched tumor and normal tissue pairs analysed
showed the expression of CYP1B1 mRNA (Figure 1A). CYP1B1
showed statistically significant downregulation across the tumor
stages at the transcriptional level in 28/36 pairs as analyzed by
qRT-PCR (Figure 1A). As seen from the Figure 1A, five tumor
tissues (patients 135, 156, 228, 233 and 234) showed significant
upregulation of CYP1B1 mRNA, while the differential regulation
of CYP1B1 was not significant in the matched tumor and normal
tissue samples of patients19, 63 and 227. Similar to a majority of
the tumor tissues, the epithelial dysplasia (ED) lesion also showed
significant downregulation of CYP1B1.
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The expression of CYP1B1 protein was analyzed by Western
blotting in 21 pairs, of which 10 werealso used for qRT-PCR
analysis. The protein expression levels as observed from the
Western blots corroborate well with the expression profile of the
CYP1B1 mRNA levels as determined by using qRT-PCR in all but
three cases (Figure 1B). In patients 63 and 135, though the mRNA
levels were higher in tumor tissues than their corresponding
normal tissues (Figure 1A), tumor tissues showed downregulation
of CYP1B1 at the protein level (Figure 1B). In patient 226,
CYP1B1 was upregulated at the mRNA level in the tumor tissue,
but equal expression of CYP1B1 protein was observed in normal
and tumor tissues (Figure 1B). On the whole, CYP1B1 protein was
downregulated in 19/21 tumor tissues in comparison to their
corresponding normal tissues (Figure 1B). One sample (patient
226) did not show any difference in CYP1B1 level between normal
and tumor tissues, while in patient 233, it was upregulated in
tumor tissue as compared to the normal tissue (Figure 1B).
Determination of CYP1B1 protein levels by
immunohistochemistry
Immunohistochemistry was carried out for a total of 7 matched
normal and tumor tissue sections, of which three cases (patients
139, 143 and 144) had also been used for qRT-PCR analysis. All
the cases analysed showed lower staining intensity in tumor
sections as compared to the matched normal sections (Figure 1C).
It is evident from the Immunohistochemistry as well as the
Western blot analysis that the CYP1B1 proteinis expressed in all
normal tissues analysed and ispredominantly downregulated in
tumor tissues.
Figure 1. Expression profiling of CYP1B1 in OSCC. (A) qRT-PCR analysis of CYP1B1 in 36 matched normal and tumor pairs, and one epithelial
dysplasia sample with its corresponding normal tissue. Each bar represents an average of duplicate reactions. The numbers on the X-axis represent
patient numbers. T1,T 2,T 3 and T4 represent the different grades of tumors according to the TNM (tumor, node and metastasis) classification. ED
represents epithelial dysplasia. *** =p,0.001, * =p,0.05 and ns = not significant. (B) The Western blot analysis of 21 matched normal oral and
tumor tissues. Note the downregulation of CYP1B1 in oral tumors compared to their corresponding normal oral tissues in all but two cases. The
numbers represent the patient numbers. N and T represent normal and tumor tissues respectively. b-actin was used as a loading control. (C)
Immunohistochemical staining for CYP1B1 in matched normal and tumor tissues from patient 136. Note the reduced expression of CYP1B1 in the
tumor tissue as compared its corresponding normal tissue.
doi:10.1371/journal.pone.0027914.g001
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This study has investigated the expression profile of CYP1B1 in
a panel of 51 OSCC cases and an epithelial dysplasia case.
CYP1B1 was found to be downregulated at the mRNA level as
determined by qRT-PCR in 77.78% (28/36) of the tumor tissues
in comparison to their corresponding normal tissues and an
epithelial dysplasia case (Figure 1A). The differences in the
CYP1B1 protein levels between the matched normal and tumor
tissues affirm the differences seen at the transcriptional level for all
except three cases: patient numbers 63, 135 and 226 (Figure 1A
and 1B). The protein expression was analysed using two different
techniques, namely Western blotting and Immunohistochemistry.
On the whole, 92.86% (26/28) of the cases showed a clear-cut
downregulation of CYP1B1 in tumor tissues as compared to their
matched normal tissues (Figure 1B and 1C and Table S1). Further,
the expression profile of CYP1B1 does not seem to be dependent
on the gender of the patients since the downregulation of CYP1B1
is observed in both males as well as in females (Table S1). For
example, the male patient 110 and the female patient 101 show
downregulation of CYP1B1 at both the mRNA and the protein
levels (see Figure 1B and Table S1). Thus unlike the previous
reports in mouse Leydig cells and endometrial cancer [16,17], the
downregulation of CYP1B1 does not seem to be governed by
estrogen. However, similar to our study, the absence of gender
differences in the pattern of CYP1B1 expression has also been
observed recently in OSCC [18,19]. On the whole, differential
expression of CYP1B1 was found to be independent of the site of
the lesion, gender of the patient, TNM status and other etiological
factors such as tobacco and alcohol consumption (Figure S1). The
observation of CYP1B1’s expression in all the normal tissues along
with its downregulation in tumor tissues is contradictory to
numerous earlier reports regarding the expression profile of
CYP1B1 in other cancers of brain, kidney, lung, colon, bladder,
breast, prostate, endometrium, ovaries and esophagus [8–11].
Nagraj et al. [3] observed that the basal transcript level of
CYP1B1 was highest in the non-malignant and pre-malignant oral
cell lines compared to the oral cancer cell line. Also the rate and
magnitude of induction of CYP1B1 by cigarette smoke condensate
was the highest in the non-malignant normal cells followed by the
pre-malignant cells and then the tumor cells [3]. These
observations, though made in an in vitro system, corroborate well
in terms of the difference observed in the levels of CYP1B1
transcription between normal and tumor tissues.
Our study is not the first one to document the expression profile of
CYP1B1 in OSCC [18,19]. However, contrasting observations have
been made with respect to the expression of CYP1B1 in OSCC
tumor tissues. For example, unlike our observations, Shatalova et al.
[19] have documented the upregulation of CYP1B1 in a study on the
head and neck squamous cell carcinoma which included only 19.5%
of oral lesions. This difference might be due different kinds of oral
lesions examined by us and Shatalova et al. [19]. On the other hand,
similar to our observations, Kolokythas et al. [18] showed down-
regulation of CYP1B1at the mRNA level only in OSCC from oral
brush cytology samples. Ours is the only study documenting the
CYP1B1 downregulation in matched tumor and normal OSCC
samples at both the transcriptional and the translational levels
(Figure 1 and Table S1).
The downregulation of CYP1B1 has also been reported in
melanoma and endometrial cancer [17,20], although many other
reports have contradictory observations and demonstrated the
upregulation of CYP1B1 in endometrial tumors [11]. The reason
behind the observed downregulation of CYP1B1 in tumor tissues
can only be speculated upon. CYP1B1 is regulated by the aryl
hydrocarbon receptor (AhR) and AhR nuclear translocator
(ARNT) complex (AhR/ARNT), apart from many other key
transcription factors [11]. The AhR/ARNT complex functions as
an intracellular receptor for a variety of environmental toxicants
like polycyclic aromatic hydrocarbons (e.g., benzo[a]pyrene),
polyhalogenated hydrocarbons, dibenzofurans, and the potent
small-molecular-weight toxicant, 2,3,7,8-tetrachlorodibenzo-p-di-
oxin (TCDD or dioxin) [21]. Most of these are tobacco derived
carcinogens [21]. The binding of these ligands to the AhR/ARNT
complex enables its translocation to the nucleus where it trans-
criptionally activates a plethora of genes, including CYP1B1 [11].
The induction of CYP1B1 in the oral mucosa has also been shown
to be majorly due to tobacco associated polycyclic aromatic
hydrocarbons (PAH) [4,7] anda major regulator associated with
PAH is AhR. As seen from Table S1, a majority of the patients
involved in this study are tobacco consumers. The transcription
induced by AhRis known to be repressed by AhRR (AhR
repressor) [22]. Constitutive expression of AhRR has been shown
to make cells non-responsive to agents that would otherwise induce
CYP1A1 [23]. Similar to CYP1A1, the induction of CYP1B1 also is
governed by AhR. Thus, the levels of AhRR can be speculated to
govern downregulation of CYP1B1 in tumor tissues. Apart
fromAhRR, epigenetic modifications such as promoter methyla-
tion of CYP1B1 in tumor tissues could also account for the
downregulation of CYP1B1. Interestingly, this mechanism has
been documented in melanoma [20]. Further, the level of miR-
27b was shown to be inversely correlated with the expression of
CYP1B1 in breast cancer tissue [24]. Thus, miRNAs such as miR-
27b could also be contributing factors for its regulation. However,
these possibilities need to be explored in future.
The tumor-specific expression pattern of CYP1B1 has been
suggested to be exploited for the developmentof targeted anticancer
therapies [9,14]. Our study indicates that caution should be
observed as this therapy may not be applicable universally to all
cancers. The fact that CYP1B1 expression is higher in the normal
tissues might aid to the development of chemopreventive drugs for
oral cancer. In the light of the knowledge that CYP1B1 plays a role
in carcinogenesis [9,11,12], drugs that inhibit CYP1B1 might be
useful prophylactic agents. During a clinical examination of the oral
cavity of a patient, it is often possible to distinguish normal tissue,
premalignant lesion (e.g., leukoplakia) and malignant tumor. An
Indian survey showed that 80% of the malignancies of the oral
cavity arise from premalignant lesions, such as leukoplakia,
erythroplakia, and oral submucous fibrosis [25]. The presence of
such premalignant lesions would enable prophylactic treatments
which otherwise are not possible in most of other cancers. Apart
from drugs that inhibit CYP1B1, prodrugs that are activated by
CYP1B1 might also be used as prophylactic drugs since they would
resultindepletionofthe cellsexpressing it,enablingreductioninthe
risk to develop a malignant lesion.
In summary, the CYP1B1 downregulation in oral tumor tissues
as compared to their matched normal tissues contradicts many
studies which state that CYP1B1 is overexpressed in tumors
[8,10,11]. This downregulation is consistent over a range of tumor
stages (TNM) and independent of the gender of the patient, site of
the lesion and etiology of the carcinogenesis. On the basis of our
observations, we suggest that a level of caution should be observed
for treatments based on CYP1B1 overexpression in tumors.
Materials and Methods
Ethics statement
This research followed the tenets of the Declaration of Helsinki,
and the informed written consent for research was obtained from
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ethics committee of the Bangalore Institute of Oncology.
Clinical material
A total of 51 matched oral tumor and normal tissues, one
epithelial dysplasia (ED) along with its matched normal tissue as
well as paraffin-sections from seven matched tumor and normal
tissues (Table S1) were ascertained at the Bangalore Institute of
Oncology, Bangalore, and R.L. Jalappa Hospital and Research
Center, Kolar, both located in the state of Karnataka, India. The
specimens from patients undergoing either surgical resection or
biopsy of the oral cancerous lesion and the adjacent normal
mucosa (approximately 5 cm from the lesion) were collected in
RNAlater
TM (Sigma-Aldrich, USA) immediately upon surgery.
The patients were not under any treatment at the time of the
surgery. Tumors were classified according to TNM (Tumor, Node
and Metastasis) classification based on the UICC (Union for
International Cancer Control, Switzerland; http://www.uicc.org/
resources/how-use-tnm-classification).
Total RNA isolation and first-strand cDNA synthesis
Total RNA was isolated from 36 matched tumor and normal
tissue pairs, and one epithelial dysplasia lesion along with its
matched normal using TRI ReagentH (Sigma-Aldrich, USA). The
first-strand cDNA was synthesized using the RevertAid
TM H
Minus First Strand cDNA synthesis kit (MBI Fermentas, Canada)
using 1.5 mg RNA and random hexamer primers in a 20 ml
reaction as per the manufacturer’s protocol.
Quantitative RT-PCR analysis
Following primers for quantitative RT-PCR (qRT-PCR)
analysis were synthesized by Sigma-Aldrich (Bangalore): GAPDH
forward (59- GAAGGTGAAGGTCGGAGTC-39) and reverse
(59-GAAATCCCATCACCATCTTC-39) [26]; and, CYP1B1
forward (59TACCGGCCACTATCACTGACATCTTC-39) and
reverse (59TGGATCAGGTCGTGGGGAGGGACC-39). Com-
plementary DNA (cDNA) equivalent to 10 ng of total RNA was
used for qRT-PCR reactions. All the qRT-PCR reactions were
carried out usingDynamo SYBR green mix(Finnzymes,Finland) in
an ABI PrismH 7000 sequence detection system (Applied Biosys-
tems, USA). The analysis has been done using the SDS 2 software
(Applied Biosystems, USA). GAPDH was used as a normalizing
control [26]. Normalized values for CYP1B1 expression in tumor
and normal tissues were calculated as follows: DC(t) Tumor =
C(t)CYP1B1 -C (t)GAPDH,a n dDC(t) Normal = C(t)CYP1B1 -C (t)GAPDH.
Where, C(t) is the cycle number at which the fluorescence intensity
crosses the default threshold value of 0.2 and DC(t) represents the
CYP1B1 expression normalized to GAPDH. DDC(t) (relative CYP1B1
expression) is equal to DC(t) Tumor - DC(t) Normal.
Western hybridization
Tissue lysates were prepared from matched normal and tumor
tissues separately by homogenizing the tissue (,100 mg) in
CellLytic
TM MT Mammalian Tissue Lysis/Extraction Reagent
(Sigma-Aldrich, USA) supplemented with 1X protease inhibitor
cocktail (Sigma-Aldrich, USA). Equal amount of protein was
resolved on a 10% SDS-PAGE and then transferred onto a PVDF
membrane (PerkinElmer Life Sciences, USA). For Western
hybridization, rabbit polyclonal anti-CYP1B1 (Santa Cruz Bio-
technology, USA) and mouse monoclonal b-actin (Sigma-Aldrich,
USA) primary antibodies were used. The signals were detected
using HRP-conjugated goat anti-rabbit or goat anti-mouse
secondary antibodies (Bangalore Genei, India), Western Lightning
Chemiluminescence Reagent Kit (PerkinElmer Life Sciences,
USA) and X-ray films (Kodak, India).
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue sections (5 mm
thick) prepared on poly-L-lysine solution (Sigma-Aldrich, USA)
coated microscopy slides were dewaxed in xylene and rehydrated to
water through decreasing percentages of ethanol prepared in
distilled water. The antigen retrieval step was carried out using
sodium citrate buffer (2.96 g/l sodium citrate prepared in distilled
water, pH=6). Endogenous peroxidase activity was quenched with
freshly prepared 1% H2O2 in 1X PBS (phosphate buffered saline/
0.05 M Na2HPO4, 0.05 M NaH2PO4 and 0.15 M NaCl, pH 7.4)
for 30 min at room temperature in dark. Nonspecific antibody
bindingwasblocked with2% BSAin1X PBST(phosphate buffered
saline with 0.1% tween) for 1 hr at room temperature in a
humidified chamber. Rabbit polyclonal anti-CYP1B1 primary
antibody was allowed to hybridize overnight at 4uC. Post washes,
HRP-conjugated goat anti-rabbit secondary antibody was added.
After washes, the sections were exposed to 1 mg/ml DAB (Sigma-
Aldrich, USA) in 1X PBS and 1% H2O2. Subsequent to washes, the
sections were counterstained with hematoxylin, progressively
dehydrated using ethanol gradation and mounted in DPX
mountant (S.D. Fine-Chem Ltd., India). The sections were
analysedunder 40x using a Olympus microscope.
Statistics
The significance of differences in the mRNA expression levels in
the qRT-PCR analysis was assessed by two-tailed student’s t-test
using the GraphPad PRISMH version 5 software (GraphPad
Software Inc., USA). For determining the statistical significance of
the correlationbetween the relative expression of CYP1B1 and
gender of the patient, site of the lesion, and tobacco and alcohol
consumption by the patient, we used the unpaired t-test with
Welch’s correction. While one-way ANOVA followed by a post-
test (Tukey’s multiple comparison test) was used to determine
whether the levels of CYP1B1 were dependent on the TNM of the
tumors. A probability value of p,0.05 was assumed to be
significant.
Supporting Information
Figure S1 Correlation of CYP1B1 expression with clin-
icopathological features of the patients. (A) The graph
shows the relative expression of CYP1B1in OSCC tumor tissues
compared to their matched normal tissues in female and male
patients.Note that the relative expression of CYP1B1 was observed
to be independent of the gender of the patient. (B)The graph
shows the relative expression of CYP1B1 in various grades of the
tumors as per the TNM classification. T1,T 2,T 3 and T4 represent
the different grades of tumors according to the TNM (tumor, node
and metastasis) classification. Note that the status of CYP1B1
expression did not show any significant correlation with the TNM
of the tumor tissues. (C)The graph shows the relative expression of
CYP1B1 with respect to the site of the lesions. Note that the
expression of CYP1B1 did not vary significantly between the BM
(buccal mucosa) and other sites of the lesion. Since most of the
lesions were from the buccal mucosa, the comparison was carried
out between buccal mucosa and all the other sites combined.
(D) The graph shows that the relative expression of CYP1B1 did
not significantly differ between consumers and non-consumers
of tobacco, areca nut, betel nut and alcohol. Abbreviation: ns
represents statistically non-significant data.
(TIF)
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tients included in the study. Information regarding the 51
cases and one epithelial dysplasia (ED) included in the study with
respect to age, sex, tumor node metastasis (TNM) classification,
site of lesions, etiology (habits) and, the expression profile of
CYP1B1 at the mRNA level and the protein levels are given.
Abbreviations: BM, buccal mucosa; N.T, downregulation in
tumor tissues; N,T, upregulation in tumors; ns, statistically non
significant; WB, Western blotting; and IHC, immunohistochem-
istry.
(PDF)
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